A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer IR-NMIBC Following Transurethral Resection of Bladder Tumor TURBT

Brief Summary

Type:
Bladder

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06111235

Study #:
STUDY00160138

Start Date:
Sep 25, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06111235

View Complete Trial Details & Eligibility at ClinicalTrials.gov